Aurinia Pharmaceuticals Inc
AUPH
Positions held
Your positionsAUPH isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Aurinia Pharmaceuticals is well-positioned in the biotechnology industry, focusing on innovative treatments that address unmet medical needs, which can lead to significant market opportunities.
- In Q2 2026, Aurinia reported a revenue increase of 7% compared to the previous quarter, reaching $83 million.
- The company's gross margin improved to 92.1%, up from 91.6% in the prior quarter, indicating strong operational efficiency.
- Despite recent growth, Aurinia's financials show volatility, with a net income loss of $78.02 million in 2023, reflecting challenges in profitability.
- The operating margin was negative at -52.2% in 2023, highlighting ongoing operational struggles.
- Aurinia's trailing P/E ratio stands at 6.88, which may suggest undervaluation, but also reflects market skepticism about future earnings growth.
Fundamentals
| Market cap | $2.16B | Enterprise value | $1.78B | Trailing P/E | 7.11 | Forward P/E | 15.21 |
| PEG | — | Price / book | 3.51 | Beta | 1.61 | Dividend yield | 0.00% |
| Revenue growth | 18.9% | Earnings growth | 75.5% | Gross margin | 77.9% | Operating margin | 55.7% |
| Profit margin | 100.8% | ROE | 66.1% | ROA | 15.5% | Debt / equity | 0.10 |
| Current ratio | 5.42 | Free cash flow | $147.82M | Analyst recommendation | none | Mean target | $17.86 |
| 52w high | $19.25 | 52w low | $10.90 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $83.2M | $77.7M | $77.1M | $73.5M | $70.0M | — |
| Op margin | 55.7% | 53.3% | 43.1% | 40.5% | 28.8% | — |
| Net income | $37.4M | $34.4M | $211M | $31.6M | $21.5M | — |
| Gross margin | 92.1% | 91.6% | 88.6% | 88.9% | 89.8% | — |
| Gross profit | $76.7M | $71.2M | $68.3M | $65.3M | $62.9M | — |
| Operating income | $46.3M | $41.4M | $33.2M | $29.7M | $20.2M | — |
- Revenue +7% vs prior quarter ($83M vs $78M).
- Gross margin 92.1% (was 91.6% prior quarter).
- Operating margin expanded to 55.7%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $283M | $235M | $176M | $134M | — |
| Op margin | 37.6% | 7.8% | -52.2% | -83.2% | — |
| Net income | $287M | $5.8M | -$78.0M | -$108M | — |
| Gross margin | 88.5% | 88.0% | 91.9% | 95.8% | — |
| Gross profit | $250M | $207M | $161M | $128M | — |
| Operating income | $107M | $18.4M | -$91.7M | -$111M | — |
Headlines — watch
• [WARN · legal] Aurinia Settles Patent Lawsuit With Teva; Shares Rise After Hours
• [WARN · legal] Could Aurinia Pharmaceuticals (AUPH) Stock Win Big After its LUPKYNIS Patent Settlement With Teva Pharmaceuticals (TEVA)
News
2026-09-16 · Aurinia’s (AUPH) Profits Surge While Its One Drug Just Got Company
2026-09-04 · Immatics and 4 More Stocks See Action From Activist Investors
2026-09-03 · LB Pharmaceuticals Names Joseph Miller CFO
2026-08-20 · How Investors Are Reacting To Aurinia Pharmaceuticals (AUPH) Extended Voclosporin Exclusivity And Share Buyback
2026-08-20 · Aurinia Pharmaceuticals (AUPH) Stock Still Looks Cheap After A 74% Gain
2026-08-19 · AUPH Stock Rallies 6% After-Hours — Here’s Why
2026-08-19 · Aurinia Settles Patent Lawsuit With Teva; Shares Rise After Hours
2026-08-19 · Aurinia Settles Patent Litigation with Teva
2026-08-07 · RBC Adjusts PT on Aurinia Pharmaceuticals to $16 From $15, Keeps Sector Perform Speculative Risk Rating
2026-08-06 · Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimates
2026-08-06 · Aurinia: Q2 Earnings Snapshot
Price (daily)
Full chart · RSI · MACD · patterns